Completed PHASE3 INTERVENTIONAL NCT00000174

Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)

Sponsor: Novartis

Conditions Alzheimer Disease Cognition Disorders

Updated 7 times since 2017 Last updated: Jun 23, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Alzheimer Disease and Cognition Disorders and is currently completed. Novartis leads this study, which shows 7 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Feb 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Feb 2020 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis

Data source: National Institute on Aging (NIA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Dallas, United States , Denver, United States , Durham, United States , Fort Lauderdale, United States , Indianapolis, United States , Lakewood, United States , Miami, United States , New York, United States , Oklahoma City, United States , Orange, United States and 5 more locations